COVID-19 Death and BCG Vaccination Programs Worldwide

Autor: Yahya H. Dallal Bashi, Feras Jassim Jirjees, Hala Jehad Al-Obaidi
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Tuberculosis and Respiratory Diseases, Vol 84, Iss 1, Pp 13-21 (2021)
Dallal Bashi, Y H, Jirjees, F J & Al-Obaidi, H J 2020, ' COVID-19 death and BCG vaccination programs worldwide ', Tuberculosis and respiratory diseases . https://doi.org/10.4046/trd.2020.0063
Tuberculosis and Respiratory Diseases
ISSN: 2005-6184
1738-3536
Popis: Several clinical trials are being conducted worldwide to investigate the protective effect of the bacillus Calmette-Guerin (BCG) vaccine against death in healthcare providers who are working directly with coronavirus disease 2019 (COVID-19) patients. Clinical studies suggested that certain live vaccines, particularly the BCG vaccine, could reduce the mortality due to other diseases caused by non-targeted pathogens, most probably through the nonspecific effects (heterologous effects). By the end of May 2020, the available information on the COVID-19 pandemic indicated the great effect of the BCG vaccine in reducing the number of COVID-19 death cases. The occurrence of death due to COVID-19 was found to be 21-fold lower in countries with a national BCG vaccination policy than in countries without such a policy, based on the medians of COVID-19 death case per 1 million of the population in these two groups of countries (p
Databáze: OpenAIRE